UCL School of Pharmacy

Prof Abdul Basit

Prof Abdul Basit

Professor of Pharmaceutics


UCL School of Pharmacy

Joined UCL
1st Jan 2012

Research summary

Professor Basit's research sits at the interface between drug delivery, the microbiome, 3D printing of pharmaceuticals and digital health, and is focused on forging links between basic science and clinical outcomes. He has invented a number of advanced drug delivery systems including PHLORAL™, DuoCoat™ and Soteria™. So far, this knowledge has been translated into the design of new technologies and improved disease treatments, many of which have been commercialised (Asacol 1600, Yaldigo and Octasa 1600).


Professor Basit leads a large and multi-disciplinary research group of PhD students and post-doctoral fellows. He has published over 350 papers, book chapters and abstracts, and delivered more than 250 invited research presentations. Abdul is also a serial entrepreneur and has filed multiple patents and founded the pharmaceutical companies Intract Pharma and FabRx. Abdul is a frequent speaker at international conferences, serves as a consultant to many pharmaceutical companies and is on the advisory boards of scientific journals, healthcare organisations and charitable bodies. He is the European Editor of the International Journal of Pharmaceutics. To date, Professor Basit has attracted over £100 million in investments as a principal investigator (PI) or co-PI from various financial sources including industry, UK based organisations and international funding bodies in research and technology development.


Professor Abdul Basit holds the position of Professor of Pharmaceutics at the UCL School of Pharmacy, University College London. Abdul is an internationally-leading authority on oral drug delivery, digital health and innovative technologies such as three-dimensional (3D) printing. Abdul is a world authority on translational research; he has founded two spin-out companies from UCL (FabRx and Intract Pharma), and invented a number of revolutionary drug delivery technologies that have entered the clinic. To date, more than a million patients have benefited from inventions created and developed in the Basit Research Group. 

Across his career, Abdul has received prestigious awards from the AAPS (Young Investigator Award in Pharmaceutics and Pharmaceutical Technology), Glaxo Smith Kline (Innovative Science Award), AstraZeneca (Pharmaceutical Science Award) and the Academy of Pharmaceutical Sciences (APS Science Award). In 2019, Abdul was listed amongst the World's Most Highly Influential Researchers by the Web of Science.